Home Insiders Updates Beam Therapeutics Inc. [BEAM] stock was sold by Evans John M. at the price of US$0.93 million

Beam Therapeutics Inc. [BEAM] stock was sold by Evans John M. at the price of US$0.93 million

Beam Therapeutics Inc. [BEAM] stock was sold by Evans John M. at the price of US$0.93 million
EURN Stock

In a filing, Beam Therapeutics Inc. revealed its CEO Evans John M. unloaded Company’s shares for reported $0.93 million on Oct 31. In the deal valued at $46.36 per share,20,000 shares were sold. As a result of this transaction, Evans John M. now holds 103,000 shares worth roughly $ 3.9 million.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Then, Evans John M. sold 30,000 shares, generating $1,389,225 in total proceeds. Upon selling the shares at $46.31, the CEO now owns 1,058,520 shares.

Before that, FMR LLC sold 551 shares. Beam Therapeutics Inc. shares valued at $29,892 were divested by the insider at a price of $54.25 per share. As a result of the transaction, FMR LLC now holds 0 shares, worth roughly $0.0.

BMO Capital Markets initiated its Beam Therapeutics Inc. [BEAM] rating to a Market perform in a research note published on June 17, 2022; the price target was $41. A number of analysts have revised their coverage, including Credit Suisse’s analysts, who began to cover the stock in late April with a ‘”a Neutral”‘ rating. Guggenheim began covering BEAM with “Buy” recommendation on January 05, 2022. SVB Leerink started covering the stock on October 19, 2021. It rated BEAM as “an Outperform”.

Price Performance Review of BEAM

On Monday, Beam Therapeutics Inc. [NASDAQ:BEAM] saw its stock fall -11.43% to $37.91. Over the last five days, the stock has lost -13.96%. Beam Therapeutics Inc. shares have fallen nearly -52.43% since the year began. Nevertheless, the stocks have fallen -57.66% over the past one year. While a 52-week high of $100.06 was reached on 01/04/22, a 52-week low of $27.77 was recorded on 05/12/22. SMA at 50 days reached $49.60, while 200 days put it at $52.07. A total of 1.87 million shares were traded, compared to the trading of 0.87 million shares in the previous session.

Levels Of Support And Resistance For BEAM Stock

The 24-hour chart illustrates a support level at 35.24, which if violated will result in even more drops to 32.57. On the upside, there is a resistance level at 40.05. A further resistance level may holdings at 42.19. The Relative Strength Index (RSI) on the 14-day chart is 33.00, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.95, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 79.74%. Stochastics %K at 20.89% indicates the stock is a holding.

How much short interest is there in Beam Therapeutics Inc.?

A steep rise in short interest was recorded in Beam Therapeutics Inc. stocks on Jul 14, 2022, growing by 1.62 million shares to a total of 13.24 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 11.62 million shares. There was a rise of 12.24%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 21.69% of the overall stock float, the days-to-cover ratio (short ratio) rose to 8.75.

Beam Therapeutics Inc. [BEAM] – Who Are The Largest Shareholders?

In filings from ARK Investment Management LLC, it is revealed that the company now owns 8,490,936 shares, or roughly 12.07% of the outstanding BEAM shares. In other words, the investor’s shares have fallen by -301,128 from its previous 13-F filing of 8792064.0. Additionally, The Vanguard Group, Inc. increased 10.97% of its stake after which the total value it holdings stand at $242,594,838, while BlackRock Fund Advisors added 18.77% of its stake to hold $205.25 million in the firm. At present, SSgA Funds Management, Inc. is holding 3,336,327 shares valued at $158.94 million. Redmile Group LLC owned 1,849,887 shares of the company at the time of its most recent 13F filing, worth $88.13 million.


Please enter your comment!
Please enter your name here